biotinylated leucoagglutinin Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Vector Laboratories biotinylated phaseolus vulgaris leucoagglutinin
    Cell surface asialoglycans regulates CRT-mediated PrCR. a , b Treatment with neuraminidase led to the removal of sialic acids from the cell surface of HL60 cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cell surface sialic acids were examined by staining with EBL (a) and MAL (b) by flow cytometry analysis. EBL, Elderberry Bark Lectin; MAL, Maackia Amurensis Lectin II. c , d Examination of cell surface CRT and <t>PHA-L</t> binding sites on cancer cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Recombinant CRT ( c ) and PHA-L ( d ) binding after treatment were measured by flow cytometry. e , f Phagocytosis of cancer cells with neuraminidase treatment. In vitro Phagocytosis assays were performed with HL60, K562, DLD-1, and SW620 cells treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu) as target cells. Mouse bone marrow-derived ( e ) and human peripheral blood monocyte-derived ( f ) macrophages were used for the assay. Phagocytosis was normalized to the maximal response in the experiments. n = 3. * P
    Biotinylated Phaseolus Vulgaris Leucoagglutinin, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biotinylated phaseolus vulgaris leucoagglutinin/product/Vector Laboratories
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    biotinylated phaseolus vulgaris leucoagglutinin - by Bioz Stars, 2022-09
    94/100 stars
      Buy from Supplier

    80
    Vector Laboratories biotinylated goat anti pha l
    Cell surface asialoglycans regulates CRT-mediated PrCR. a , b Treatment with neuraminidase led to the removal of sialic acids from the cell surface of HL60 cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cell surface sialic acids were examined by staining with EBL (a) and MAL (b) by flow cytometry analysis. EBL, Elderberry Bark Lectin; MAL, Maackia Amurensis Lectin II. c , d Examination of cell surface CRT and <t>PHA-L</t> binding sites on cancer cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Recombinant CRT ( c ) and PHA-L ( d ) binding after treatment were measured by flow cytometry. e , f Phagocytosis of cancer cells with neuraminidase treatment. In vitro Phagocytosis assays were performed with HL60, K562, DLD-1, and SW620 cells treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu) as target cells. Mouse bone marrow-derived ( e ) and human peripheral blood monocyte-derived ( f ) macrophages were used for the assay. Phagocytosis was normalized to the maximal response in the experiments. n = 3. * P
    Biotinylated Goat Anti Pha L, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biotinylated goat anti pha l/product/Vector Laboratories
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    biotinylated goat anti pha l - by Bioz Stars, 2022-09
    80/100 stars
      Buy from Supplier

    Image Search Results


    Cell surface asialoglycans regulates CRT-mediated PrCR. a , b Treatment with neuraminidase led to the removal of sialic acids from the cell surface of HL60 cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cell surface sialic acids were examined by staining with EBL (a) and MAL (b) by flow cytometry analysis. EBL, Elderberry Bark Lectin; MAL, Maackia Amurensis Lectin II. c , d Examination of cell surface CRT and PHA-L binding sites on cancer cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Recombinant CRT ( c ) and PHA-L ( d ) binding after treatment were measured by flow cytometry. e , f Phagocytosis of cancer cells with neuraminidase treatment. In vitro Phagocytosis assays were performed with HL60, K562, DLD-1, and SW620 cells treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu) as target cells. Mouse bone marrow-derived ( e ) and human peripheral blood monocyte-derived ( f ) macrophages were used for the assay. Phagocytosis was normalized to the maximal response in the experiments. n = 3. * P

    Journal: Nature Communications

    Article Title: Programmed cell removal by calreticulin in tissue homeostasis and cancer

    doi: 10.1038/s41467-018-05211-7

    Figure Lengend Snippet: Cell surface asialoglycans regulates CRT-mediated PrCR. a , b Treatment with neuraminidase led to the removal of sialic acids from the cell surface of HL60 cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cell surface sialic acids were examined by staining with EBL (a) and MAL (b) by flow cytometry analysis. EBL, Elderberry Bark Lectin; MAL, Maackia Amurensis Lectin II. c , d Examination of cell surface CRT and PHA-L binding sites on cancer cells. HL60 cells were treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Recombinant CRT ( c ) and PHA-L ( d ) binding after treatment were measured by flow cytometry. e , f Phagocytosis of cancer cells with neuraminidase treatment. In vitro Phagocytosis assays were performed with HL60, K562, DLD-1, and SW620 cells treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu) as target cells. Mouse bone marrow-derived ( e ) and human peripheral blood monocyte-derived ( f ) macrophages were used for the assay. Phagocytosis was normalized to the maximal response in the experiments. n = 3. * P

    Article Snippet: For CRT-binding experiments, cells were incubated with recombinant calreticulin human Fc fusion protein at 40 µg ml−1 or biotin-PHA-L 6 µg ml− 1 (B-1115, Vector laboratory) for 1 h incubated on ice.

    Techniques: Staining, Flow Cytometry, Cytometry, Binding Assay, Recombinant, In Vitro, Derivative Assay

    Identification of CRT-binding ligands on aged and malignant cells. a Screening for CRT-binding glycans with carbohydrate microarray. Purified CRT-IgG-Fc proteins were used to probe a carbohydrate microarray containing a number of different types of glycans, including N-, O- and sulfated-glycans. Anti-IgG-Fc antibody was used for detecting binding of CRT to glycans. Glyco-antigens were used at 0.05 and 0.25 μg μl −1 (left and right bars for each glycan). n = 3. Error bars represent standard deviation. b PHA-L binding to peritoneal neutrophils and macrophages at 0, 4, 6, 8, 24, and 72 h after thioglycollate injection in MRP8-Bcl2 mice. c , d Examination of cell surface CRT-binding sites on neutrophils. Bone marrow ( c ) or peritoneal neutrophils ( d ) were collected and treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cells were incubated with PBS (control; black) or recombinant CRT proteins (red) and binding of CRT was then measured by flow cytometry with PE-conjugated anti-CRT antibody. rCRT binds to mature peritoneal neutrophils but not the immature bone marrow neutrophils. Treatment with neuraminidase led to the release of CRT-binding sites. e , f Immunofluorescent staining of CRT in HL60 ( e ) and SW620 ( f ) cells. CRT localized to perinuclear regions, vesicles, and cell surface. CRT was either expressed at a low level ( e ) or limited to the perinuclear regions ( f ), while a significant portion of PHA-L staining were observed on the cell surface ( e and f ).In a – d , MFI, mean fluorescence intensity

    Journal: Nature Communications

    Article Title: Programmed cell removal by calreticulin in tissue homeostasis and cancer

    doi: 10.1038/s41467-018-05211-7

    Figure Lengend Snippet: Identification of CRT-binding ligands on aged and malignant cells. a Screening for CRT-binding glycans with carbohydrate microarray. Purified CRT-IgG-Fc proteins were used to probe a carbohydrate microarray containing a number of different types of glycans, including N-, O- and sulfated-glycans. Anti-IgG-Fc antibody was used for detecting binding of CRT to glycans. Glyco-antigens were used at 0.05 and 0.25 μg μl −1 (left and right bars for each glycan). n = 3. Error bars represent standard deviation. b PHA-L binding to peritoneal neutrophils and macrophages at 0, 4, 6, 8, 24, and 72 h after thioglycollate injection in MRP8-Bcl2 mice. c , d Examination of cell surface CRT-binding sites on neutrophils. Bone marrow ( c ) or peritoneal neutrophils ( d ) were collected and treated with heat inactivated neuraminidase (Δneu) or neuraminidase (neu). Cells were incubated with PBS (control; black) or recombinant CRT proteins (red) and binding of CRT was then measured by flow cytometry with PE-conjugated anti-CRT antibody. rCRT binds to mature peritoneal neutrophils but not the immature bone marrow neutrophils. Treatment with neuraminidase led to the release of CRT-binding sites. e , f Immunofluorescent staining of CRT in HL60 ( e ) and SW620 ( f ) cells. CRT localized to perinuclear regions, vesicles, and cell surface. CRT was either expressed at a low level ( e ) or limited to the perinuclear regions ( f ), while a significant portion of PHA-L staining were observed on the cell surface ( e and f ).In a – d , MFI, mean fluorescence intensity

    Article Snippet: For CRT-binding experiments, cells were incubated with recombinant calreticulin human Fc fusion protein at 40 µg ml−1 or biotin-PHA-L 6 µg ml− 1 (B-1115, Vector laboratory) for 1 h incubated on ice.

    Techniques: Binding Assay, Microarray, Purification, Standard Deviation, Injection, Mouse Assay, Incubation, Recombinant, Flow Cytometry, Cytometry, Staining, Fluorescence